Full Press Release Details
Third menu expansion in four years broadens intestinal parasite detection in routine care
WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Fecal Dx™ antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than fecal flotation alone, 1 Fecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526203257/en/
IDEXX Fecal Dx™ antigen testing platform menu
Since launching in 2012, more than 50 million Fecal Dx antigen tests have been run worldwide, 2 reflecting strong clinical adoption over time. With each menu expansion, Fecal Dx has grown into a scalable diagnostic platform with increasing clinical scope and practice value.
“This advancement reflects how we innovate at IDEXX, developing platforms that grow with our customers as care evolves,” said Mike Erickson, President and CEO of IDEXX. “By broadening the insight available through Fecal Dx, we’re making fecal testing easier to incorporate into everyday decision-making, helping veterinary teams reach more pets with greater confidence.”
Taenia and Echinococcus species are recognized by the Companion Animal Parasite Council (CAPC) as clinically important parasites, 3,4 with growing relevance for veterinarians worldwide. In particular, in areas where Echinococcus species is endemic, it can pose a significant zoonotic risk and remains a notable concern in parts of Europe, the United States and Canada. With this addition, Fecal Dx antigen testing now detects seven of the most clinically relevant intestinal parasite groups, including hookworm, roundworm, whipworm, flea tapeworm, taeniid tapeworm, Cystoisospora and Giardia (in select panels).
“The addition of taeniid tapeworm detection to IDEXX Fecal Dx makes this an even more complete intestinal parasite screen for cats and dogs,” said Michael Rose, DVM, Managing Owner, Monticello Animal Hospital.* “This allows veterinarians to institute medical treatment early, which helps protect pet health and reduce zoonotic risk to owners.”
Beginning in late June, Fecal Dx antigen testing panels and profiles for IDEXX Reference Laboratories customers in the United States and Canada will automatically include detection of taeniid tapeworm at no additional cost.
For more information, please visit the Fecal Dx antigen testing web page.
* Dr. Rose has received compensation for consulting services he has provided to IDEXX.
References
1.
Burton KW, Michael H, Drake C. The utility of coproantigen testing in screening populations. Vet Parasitol . 2025;336:110459. doi:10.1016/j.vetpar.2025.110459
2.
Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: IDEXX Fecal Dx antigen test results collected January 2012–April 2026.
3.
Companion Animal Parasite Council. CAPC guidelines: Taenia spp. Updated February 7, 2025. Accessed May 5, 2026. www.capcvet.org/guidelines/taenia
4.
Companion Animal Parasite Council. CAPC guidelines: Echinococcus spp. Updated February 7, 2025. Accessed May 5, 2026. www.capcvet.org/guidelines/echinococcus-spp
About IDEXX
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com .
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260526203257/en/
Media Relations media@idexx.com Investor Relations investorrelations@idexx.com
Source: IDEXX Laboratories, Inc.
Released May 26, 2026